|
|
 Previous Article | Table of Contents | Next Article 
Idiotype Immunization Combined With Granulocyte-Macrophage
Colony-Stimulating Factor in Myeloma Patients Induced Type I, Major
Histocompatibility Complex-Restricted, CD8- and CD4-Specific T-Cell
Responses
Anders Österborg,
Qing Yi,
Lotta Henriksson,
Jan Fagerberg,
Susanne Bergenbrant,
Mahmood Jeddi-Tehrani,
Ulla Rudén,
Ann-Kari Lefvert,
Göran Holm, and
Håkan Mellstedt
From the Departments of Oncology (Radiumhemmet) and Medicine,
Karolinska Hospital, Swedish Institute for Infectious Disease Control,
Stockholm; and the Department of Experimental Oncology, Uppsala
University, Uppsala, Sweden.
Idiotypic structures expressed on the myeloma Ig protein might be
regarded as a tumor-specific antigen. Five patients with IgG myeloma
were immunized with the purified serum M-component by repeated
intradermal injections together with soluble granulocyte-macrophage colony-stimulating factor (GM-CSF). All patients developed an idiotype
(Id)-specific T-cell immunity, defined as blood T cells predominantly
secreting interferon- (IFN-) and interleukin-2 (IL-2) (type I
cells). Id-specific DNA synthesis was induced in one patient.
Delayed-type hypersensitivity against the Id was not evoked. The
specific IFN-/IL-2 T-cell response was inhibited (46% to 100%) by
a major histocompatibility complex (MHC) class I monoclonal antibody
(MoAb) in all five patients. A 5% to 37% inhibition by an MHC class
II MoAb was seen in four patients. CD4+ as well as
CD8+ T cells enriched by magnetic microbeads contained
Id-specific cells. The T cells recognized peptides corresponding to the
complementarity-determining regions 1, 2, and 3 of the heavy chain of
the Id. There was a transient rise of B cells producing IgM
anti-idiotypic antibodies in all patients. The results indicate that
immunization of myeloma patients using the autologous M-component and
soluble GM-CSF may evoke an Id-specific predominantly MHC class
I-restricted type I T-cell response.
Blood, Vol. 91 No. 7 (April 1), 1998:
pp. 2459-2466
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Cohen, J. Haimovich, and N. Hollander
Dendritic Cell-Based Therapeutic Vaccination against Myeloma: Vaccine Formulation Determines Efficacy against Light Chain Myeloma
J. Immunol.,
February 1, 2009;
182(3):
1667 - 1673.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. O. Abdalla, P. Kokhaei, L. Hansson, H. Mellstedt, and A. Osterborg
Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC)
Ann. Onc.,
June 1, 2008;
19(6):
1172 - 1179.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. v. Rhee
Idiotype Vaccination Strategies in Myeloma: How to Overcome a Dysfunctional Immune System
Clin. Cancer Res.,
March 1, 2007;
13(5):
1353 - 1355.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Hansson, A. O. Abdalla, A. Moshfegh, A. Choudhury, H. Rabbani, B. Nilsson, A. Osterborg, and H. Mellstedt
Long-term Idiotype Vaccination Combined with Interleukin-12 (IL-12), or IL-12 and Granulocyte Macrophage Colony-Stimulating Factor, in Early-Stage Multiple Myeloma Patients
Clin. Cancer Res.,
March 1, 2007;
13(5):
1503 - 1510.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. O. Abdalla, L. Hansson, I. Eriksson, B. Nasman-Glaser, E. D. Rossmann, H. Rabbani, H. Mellstedt, and A. Osterborg
Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma - evaluation of T-cell responses by different read-out systems
Haematologica,
January 1, 2007;
92(1):
110 - 114.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bertinetti, K. Zirlik, K. Heining-Mikesch, G. Ihorst, H. Dierbach, C. F. Waller, and H. Veelken
Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
Cancer Res.,
April 15, 2006;
66(8):
4496 - 4502.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Jalili, S. Ozaki, T. Hara, H. Shibata, T. Hashimoto, M. Abe, Y. Nishioka, and T. Matsumoto
Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma
Blood,
November 15, 2005;
106(10):
3538 - 3545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.A. Schey, P. Fields, J.B. Bartlett, I.A. Clarke, G. Ashan, R.D. Knight, M. Streetly, and A.G. Dalgleish
Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma
J. Clin. Oncol.,
August 15, 2004;
22(16):
3269 - 3276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Hansson, H. Rabbani, J. Fagerberg, A. Osterborg, and H. Mellstedt
T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma
Blood,
June 15, 2003;
101(12):
4930 - 4936.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Rasmussen, L. Hansson, A. Osterborg, H. E. Johnsen, and H. Mellstedt
Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells
Blood,
June 1, 2003;
101(11):
4607 - 4610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Milazzo, V. L. Reichardt, M. R. Muller, F. Grunebach, and P. Brossart
Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA
Blood,
February 1, 2003;
101(3):
977 - 982.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Chiriva-Internati, Z. Wang, E. Salati, K. Bumm, B. Barlogie, and S. H. Lim
Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma
Blood,
July 18, 2002;
100(3):
961 - 965.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-J. Wen, R. Min, G. Tricot, B. Barlogie, and Q. Yi
Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy
Blood,
May 1, 2002;
99(9):
3280 - 3285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Gong, S. Koido, D. Chen, Y. Tanaka, L. Huang, D. Avigan, K. Anderson, T. Ohno, and D. Kufe
Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12
Blood,
April 1, 2002;
99(7):
2512 - 2517.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M.-Y. Sze, G. Giesajtis, R. D. Brown, M. Raitakari, J. Gibson, J. Ho, A. G. Baxter, B. Fazekas de St Groth, A. Basten, and D. E. Joshua
Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+CD57+CD28- compartment
Blood,
November 1, 2001;
98(9):
2817 - 2827.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gorschluter, C. Ziske, A. Glasmacher, and I. G. H. Schmidt-Wolf
Current Clinical and Laboratory Strategies to Augment the Efficacy of Immunotherapy in Multiple Myeloma
Clin. Cancer Res.,
August 1, 2001;
7(8):
2195 - 2204.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. E. Kay, T. L. Leong, N. Bone, D. H. Vesole, P. R. Greipp, B. Van Ness, M. M. Oken, and R. A. Kyle
Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients
Blood,
July 1, 2001;
98(1):
23 - 28.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-J. Wen, B. Barlogie, and Q. Yi
Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells
Blood,
March 15, 2001;
97(6):
1750 - 1755.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Lim, Z. Wang, M. Chiriva-Internati, and Y. Xue
Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma
Blood,
March 1, 2001;
97(5):
1508 - 1510.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Li, M. Bendandi, Y. Deng, C. Dunbar, N. Munshi, S. Jagannath, L. W. Kwak, and H. K. Lyerly
Tumor-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells
Blood,
October 15, 2000;
96(8):
2828 - 2833.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Pope, R. D. Brown, J. Gibson, E. Yuen, and D. Joshua
B7-2-positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy
Blood,
August 15, 2000;
96(4):
1274 - 1279.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Osterroth, A. Garbe, P. Fisch, and H. Veelken
Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells
Blood,
February 15, 2000;
95(4):
1342 - 1349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. van Baren, F. Brasseur, D. Godelaine, G. Hames, A. Ferrant, F. Lehmann, M. Andre, C. Ravoet, C. Doyen, G. C. Spagnoli, et al.
Genes Encoding Tumor-Specific Antigens Are Expressed in Human Myeloma Cells
Blood,
August 15, 1999;
94(4):
1156 - 1164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Massaia, P. Borrione, S. Battaglio, S. Mariani, E. Beggiato, P. Napoli, C. Voena, A. Bianchi, M. Coscia, B. Besostri, et al.
Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy
Blood,
July 15, 1999;
94(2):
673 - 683.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. L. Reichardt, C. Y. Okada, A. Liso, C. J. Benike, K. E. Stockerl-Goldstein, E. G. Engleman, K. G. Blume, and R. Levy
Idiotype Vaccination Using Dendritic Cells After Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma---A Feasibility Study
Blood,
April 1, 1999;
93(7):
2411 - 2419.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Raje, J. Gong, D. Chauhan, G. Teoh, D. Avigan, Z. Wu, D. Chen, S. P. Treon, I. J. Webb, D. W. Kufe, et al.
Bone Marrow and Peripheral Blood Dendritic Cells From Patients With Multiple Myeloma Are Phenotypically and Functionally Normal Despite the Detection of Kaposi's Sarcoma Herpesvirus Gene Sequences
Blood,
March 1, 1999;
93(5):
1487 - 1495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Barlogie, S. Jagannath, K.R. Desikan, S. Mattox, D. Vesole, D. Siegel, G. Tricot, N. Munshi, A. Fassas, S. Singhal, et al.
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Blood,
January 1, 1999;
93(1):
55 - 65.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
